Evolocumab in Acute Coronary Syndrome: A Double-Blind Randomized Placebo Controlled Study
Phase of Trial: Phase II
Latest Information Update: 05 Nov 2019
Price : $35 *
At a glance
- Drugs Evolocumab (Primary)
- Indications Acute coronary syndromes
- Focus Therapeutic Use
- Acronyms EVACS
- 06 Aug 2019 Planned primary completion date changed from 30 Jun 2019 to 30 Dec 2019.
- 20 Jun 2018 Status changed from not yet recruiting to recruiting.
- 08 May 2018 New trial record